Goldman Sachs’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $121K | Sell |
149,178
-6,037
| -4% | -$4.89K | ﹤0.01% | 4845 |
|
|
2025
Q1 | $119K | Buy |
155,215
+6,889
| +5% | +$5.29K | ﹤0.01% | 4789 |
|
|
2024
Q4 | $189K | Buy |
148,326
+53,165
| +56% | +$67.8K | ﹤0.01% | 4678 |
|
|
2024
Q3 | $197K | Buy |
95,161
+20,238
| +27% | +$41.9K | ﹤0.01% | 4498 |
|
|
2024
Q2 | $285K | Buy |
74,923
+7,496
| +11% | +$28.6K | ﹤0.01% | 4235 |
|
|
2024
Q1 | $320K | Sell |
67,427
-2,038
| -3% | -$9.66K | ﹤0.01% | 4169 |
|
|
2023
Q4 | $297K | Buy |
69,465
+1,777
| +3% | +$7.59K | ﹤0.01% | 4190 |
|
|
2023
Q3 | $209K | Buy |
67,688
+43,900
| +185% | +$136K | ﹤0.01% | 4245 |
|
|
2023
Q2 | $107K | Sell |
23,788
-25,708
| -52% | -$116K | ﹤0.01% | 4556 |
|
|
2023
Q1 | $282K | Buy |
49,496
+33,732
| +214% | +$192K | ﹤0.01% | 4374 |
|
|
2022
Q4 | $95.2K | Sell |
15,764
-5,971
| -27% | -$36.1K | ﹤0.01% | 4683 |
|
|
2022
Q3 | $144K | Sell |
21,735
-22,560
| -51% | -$149K | ﹤0.01% | 4827 |
|
|
2022
Q2 | $232K | Buy |
44,295
+20,205
| +84% | +$106K | ﹤0.01% | 4833 |
|
|
2022
Q1 | $166K | Sell |
24,090
-89,245
| -79% | -$615K | ﹤0.01% | 5155 |
|
|
2021
Q4 | $1.41M | Buy |
113,335
+104,676
| +1,209% | +$1.3M | ﹤0.01% | 3756 |
|
|
2021
Q3 | $271K | Sell |
8,659
-9,958
| -53% | -$312K | ﹤0.01% | 4715 |
|
|
2021
Q2 | $533K | Sell |
18,617
-24,892
| -57% | -$713K | ﹤0.01% | 4387 |
|
|
2021
Q1 | $1.89M | Buy |
+43,509
| New | +$1.89M | ﹤0.01% | 3430 |
|
|
2020
Q4 | – | Sell |
-83,200
| Closed | -$2.51M | – | 4730 |
|
|
2020
Q3 | $2.51M | Buy |
+83,200
| New | +$2.51M | ﹤0.01% | 2785 |
|